Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

The Impact of AI on Clinical Trials: Four Key Benefits and Three Major Risks

August 1, 2025 | AI, Patient Retention, clinical trials, patient recruitment 

Artificial intelligence (AI) in clinical research has the potential to accelerate patient access to new treatments by streamlining the drug development process and helping to generate more robust data, which will inevitably aid regulatory decision-making.

- PMLiVE

Eloise Moffatt, our Vice President of Commercial, joined other industry experts during a webinar about AI trends and technologies for 2025. They discussed the benefits that AI and machine learning (ML) can bring to clinical trials and the potential pitfalls that require careful consideration.

Read more here

This content was provided by Innovative Trials

Company Details

- PMLiVE

Innovative Trials

Email
Website

 Latest Content from  Innovative Trials 

[Free Case Study Booklet] Accelerating Patient Recruitment in a global rare disease trial

See how Innovative Trials supported a Top 5 pharma to complete enrollment in a Phase 2 Lupus study

Pride Month 2023 – Innovative Trials

Innnovative Trials’ Equality & Diversity committee celebrates Pride Month

[Free Whitepaper] 5 Principles for Greater Diversity in Patient Recruitment

Discover how community engagement could enhance diversity in clinical trials patient recruitment

Innovative Trials attended the Inspire Hertfordshire Award gala dinner

Innovative Trials, a global clinical trial patient recruitment and retention company based in Hertfordshire, has been recognised for its contribution to the county’s economy and business reputation.

Navigating patients step by step on their clinical trial journey

For clinical trial participants, navigating their way through a study can sometimes seem daunting and complicated. Without the right support, around 30% are likely to drop out [1], resulting in…

Innovative Trials responds to national recommendations to tackle UK clinical trial decline

Kate Shaw, Founder & CEO, comments on the Lord report of the Lord O’Shaughnessy review into commercial clinical trials in the UK.

Innovative Trials nominates Eloise Moffett as New VP of Commercial

Eloise Moffett joins Innovative Trials as New Vice President of Commercial to drive business growth globally

Kate Shaw comments the appointment of an independent review on clinical trials in the UK.

The news comes after a report by the Association of the British Pharmaceutical Industry (ABPI) highlighted a 44% decline in industry clinical trials in the UK over the last five…

Patient Recruitment: Think Global, Act Local

Global clinical trials are a vital component of pharma R&D. Utilizing sites in multiple countries not only provides increased access to eligible and diverse patients – and therefore more robust…

Innovative Trials comments on extra funding to increase access to clinical trials for cancer patients

Kate Shaw, Innovative Trials’ Founder & CEM, reflects on the exciting news for patients affected by cancer in the UK.